Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

InterVentional Technologies

This article was originally published in The Gray Sheet

Executive Summary

Plans to begin a randomized trial in April of its Barath surgical balloon dilatation catheter at ten sites in the U.S., IVT Chairman and CEO Robert Reiss reported Feb. 3 at the fifth annual Piper Jaffray cardiovascular conference in New York City. The device also will be studied in a six-country, non-randomized Phase II trial slated to begin March 1. Phase I trials of 17 patients in the U.S. and 17 patients in Europe have been completed ("The Gray Sheet" Dec. 7, In Brief), and six month followup on ten patients has shown a 0% restenosis rate, Reiss said. IVT hopes to introduce the device in Europe in January 1994.
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT000171

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel